VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% (2025)

All information and materials on this site pertain to the US only, unless otherwise indicated.

© 2025 Bausch + Lomb.

02/07/2025

Glaucoma is the leading cause of irreversible blindness worldwide. Many believe that only elderly people get glaucoma. In truth, all age groups are at risk of developing the disease. Glaucoma does not have any noticeable symptoms until it has already progressed into irreversible vision loss, so it is vital to schedule regular eye exams, no matter your age.

INDICATION
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION
• Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued.
• Gradual changes to eyelashes may occur, including increased length, thickness, color, number of eyelashes and/or direction of eyelash growth. These changes may result in a difference in appearance of each eye. These changes are usually reversible after VYZULTA treatment is discontinued.
• Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions.
• Tell your doctor immediately about any change in your eye, any eye condition that develops, any sudden change in your vision, any eye side effects, or if you have eye surgery.
• Remove contact lenses before putting VYZULTA in your eyes. Lenses may be reinserted 15 minutes later.
• If you are using other eye drops in addition to VYZULTA, wait 5 minutes between using each type of eye drop.
• The most common side effects seen in studies were eye redness, eye irritation, eye pain, and pain after putting the drops in your eye.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information at https://bit.ly/3NSCdjW.

©2025 Bausch + Lomb. VYZ.0039.USA.25

05/05/2025

We understand it can be intimidating when you're diagnosed with open-angle glaucoma or ocular hypertension. Whether you’re newly diagnosed, exploring treatment options, or managing your condition long-term, the VYZULTA Patient Journey videos can help you better understand the next steps for your treatment. Visit to learn more VYZULTA.com about what you can expect from VYZULTA.

INDICATION
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION
• Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued.
• Gradual changes to eyelashes may occur, including increased length, thickness, color, number of eyelashes and/or direction of eyelash growth. These changes may result in a difference in appearance of each eye. These changes are usually reversible after VYZULTA treatment is discontinued.
• Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions.
• Tell your doctor immediately about any change in your eye, any eye condition that develops, any sudden change in your vision, any eye side effects, or if you have eye surgery.
• Remove contact lenses before putting VYZULTA in your eyes. Lenses may be reinserted 15 minutes later.
• If you are using other eye drops in addition to VYZULTA, wait 5 minutes between using each type of eye drop.
• The most common side effects seen in studies were eye redness, eye irritation, eye pain, and pain after putting the drops in your eye.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information at https://bit.ly/3NSCdjW.

©2025 Bausch + Lomb. VYZ.0018.USA.25

11/04/2025

Did you know that women are at a higher risk to go blind due to ocular conditions like glaucoma? Age is also a key risk factor, as are the natural hormone fluctuations women experience. Because symptoms of some ocular diseases like glaucoma are often invisible, early detection through regular eye exams and ongoing treatment can make a difference in helping to prevent future vision loss. Your vision matters.

INDICATION
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION
•Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued.
•Gradual changes to eyelashes may occur, including increased length, thickness, color, number of eyelashes and/or direction of eyelash growth. These changes may result in a difference in appearance of each eye. These changes are usually reversible after VYZULTA treatment is discontinued.
•Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions.
•Tell your doctor immediately about any change in your eye, any eye condition that develops, any sudden change in your vision, any eye side effects, or if you have eye surgery.
•Remove contact lenses before putting VYZULTA in your eyes. Lenses may be reinserted 15 minutes later.
•If you are using other eye drops in addition to VYZULTA, wait 5 minutes between using each type of eye drop.
•The most common side effects seen in studies were eye redness, eye irritation, eye pain, and pain after putting the drops in your eye.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information at https://bit.ly/3NSCdjW.

©2025 Bausch + Lomb. VYZ.0019.USA.25

15/01/2025

January is Glaucoma Awareness Month, and Bausch + Lomb would like to show our continued support for those globally impacted by this condition. Glaucoma is the leading cause of irreversible blindness, but treatments are available. This January, we encourage you to stay current with eye exams, as early diagnosis and ongoing treatment can help prevent future vision loss from glaucoma. Your vision matters.

INDICATION
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION
•Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued.
•Gradual changes to eyelashes may occur, including increased length, thickness, color, number of eyelashes and/or direction of eyelash growth. These changes may result in a difference in appearance of each eye. These changes are usually reversible after VYZULTA treatment is discontinued.
•Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions.
•Tell your doctor immediately about any change in your eye, any eye condition that develops, any sudden change in your vision, any eye side effects, or if you have eye surgery.
•Remove contact lenses before putting VYZULTA in your eyes. Lenses may be reinserted 15 minutes later.
•If you are using other eye drops in addition to VYZULTA, wait 5 minutes between using each type of eye drop.
•The most common side effects seen in studies were eye redness, eye irritation, eye pain, and pain after putting the drops in your eye.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information at https://bit.ly/3NSCdjW.

© 2025 Bausch + Lomb. VYZ.0153.USA.24

Please see full Prescribing Information for VYZULTA at https://bit.ly/3NSCdjW© 2025 Bausch + Lomb. VYZ.0183.USA.24

19/12/2024

Address

Website

http://www.VYZULTA.com/

Alerts

Be the first to know and let us send you an email when VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%:

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%